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Abstract
Chromium is considered to have positive effects on 
insulin sensitivity and is marketed as an adjunctive 
therapy for inducing glucose tolerance in cases of in-
sulin resistance (“the glucose tolerance factor”). Case 
reports on patients who received prolonged parenteral 
nutrition indeed showed that the absence of trivalent 
chromium caused insulin resistance and diabetes. How-
ever, whether patients with type 2 diabetes can develop 
a clinically relevant chromium deficiency is unclear. This 
review summarizes the available evidence regarding the 
potential effectiveness of chromium supplementation 
on glycemic control (Hemoglobin A1c levels) in patients 
with type 2 diabetes. No studies investigating the long-
term safety of chromium in humans were found. All clin-
ical trials that have been performed had a relative short 
follow-up period. None of the trials investigated whether 
the patients had risk factors for chromium deficiency. 
The evidence from randomized trials in patients with 
type 2 diabetes demonstrated that chromium supple-
mentation does not effectively improve glycemic control. 
The meta-analyses showed that chromium supplemen-
tation did not improve fasting plasma glucose levels. 
Moreover, there were no clinically relevant chromium ef-
fects on body weight in individuals with or without dia-
betes. Future studies should focus on reliable methods 
to estimate chromium status to identify patients at risk 
for pathological alterations in their metabolism associ-
ated with chromium deficiency. Given the present data, 
there is no evidence that supports advising patients with 
type 2 diabetes to take chromium supplements.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: In some patients who received prolonged par-
enteral nutrition, absence of trivalent chromium caused 
insulin resistance and diabetes and supplementation 
with trivalent chromium “cleared” this metabolic dis-
ease. The question is, whether chromium deficiency 
is a relevant factor in the cause of type 2 diabetes in 
general and whether supplementation with trivalent 
chromium can have beneficial effects in type 2 dia-
betes. Unfortunately, no reliable methods to estimate 
chromium status exists and according to current evi-
dence, chromium does not improve glycemic control in 
patients with type 2 diabetes and patients should be 
advised not to take chromium supplements.
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INTRODUCTION
Insulin resistance is an important target for pharmaco-
logical and non-pharmacological interventions in patients 
with type 2 diabetes. In addition to the well-established 
interventions, a multitude of  suggested alternative solu-
tions outside the field of  regular conventional medicine is 
available. One of  these suggested beneficial interventions 
is oral supplementation with chromium. Chromium is 
marketed as a substance that improves insulin sensitiv-
ity (being as part of  the “Glucose Tolerance Factor” 
molecule), weight loss and improving glycemic control in 
patients with diabetes[1,2]. Chromium has become the sec-
ond most popular dietary supplement after calcium in the 
United States, with sales amounting to approximately 100 
million dollars annually[1,2]. 
Some studies have demonstrated that chromium 
supplementation in chromium deficient states indeed 
led to beneficial effects[3-6]. There are strong arguments 
supporting the hypothesis that chromium supplementa-
tion improves glycemic control in chromium deficient 
patients by improving insulin sensitivity[7]. In addition, 
patients with diabetes are thought to have a chromium 
deficient status that is induced by an altered chromium 
metabolism[4,8,9]. However, other studies have suggested 
that chromium metabolism is not altered in type 2 diabe-
tes[10]. Unfortunately, cut-off  points for chromium levels 
correlating with relevant changes in glucose metabolism 
and insulin resistance are lacking. There is no clinically 
defined chromium deficiency state, nor is there a vali-
dated method for estimating the total body chromium 
status[11-13]. A reliable assessment of  the chromium status 
in biological tissues and fluids is difficult due to extremely 
low chromium levels[12]. Although some studies have 
demonstrated successful chromium level determination 
in hair, sweat, and blood, there is still no exact method 
for defining chromium deficiency[8]. In this theoretical 
framework the “diabetic state” is linked to chromium 
deficiency and chromium supplementation would amend 
glycemic control by improving insulin sensitivity. This 
review discusses chromium physiology and summarizes 
the current evidence that chromium supplementation im-
proves glycemic control in patients with type 2 diabetes.
Several case reports demonstrated beneficial effects 
of  chromium supplementation in patients requiring total 
parenteral nutrition for prolonged periods[3,5-7,14,15]. One 
case report, published in 1977, discussed a 40-year-old 
woman who had undergone a total enterectomy after 
mesenterial thrombosis and became dependent on to-
tal parenteral nutrition[14]. After three years, she started 
losing weight and developed diabetes mellitus. She was 
young, had a low body weight, and required 50 IE of  
insulin daily to reach a near-normoglycemic state. Chro-
mium deficiency was considered as a possible cause. 
The chromium concentration in her serum and hair was 
measured and found to be low [154 ng/g (N > 500 ng/g) 
and 0.55 ng/g (N = 4.9-9.5 ng/g), respectively]. She was 
treated intravenously with 250 micrograms of  chromium 
chloride daily for two weeks. This treatment decreased 
the amount of  insulin needed, and after four months of  
chromium supplementation, she remained normoglyce-
mic without insulin. After this and several other case re-
ports[3,9,14], chromium was added to parenteral nutrition as 
a standard ingredient[6]. Nevertheless, the extent of  chro-
mium supplementation necessary during total parenteral 
nutrition is still debated[16,17]. 
CHROMIUM PHYSIOLOGY 
The two most common forms of  chromium are the triva-
lent (3+) and the hexavalent (6+) forms. Chromium 6+ is 
not present in nature and is toxic. The chromium found 
in food and in dietary supplements is the trivalent form. 
Whole grain products, such as whole grain bread, vegeta-
bles, nuts, and some spices contain low concentrations of  
trivalent chromium. Chromium supplements are available 
as chromium chloride, chromium nicotinate, chromium 
picolinate, high-chromium yeast, and chromium citrate. 
Chromium chloride appears to have a poor bioavailability, 
although there is limited data on chromium absorption in 
humans[12,15,18]. 
The role of  trivalent chromium in glucose metabo-
lism has been known since the 1950s[15]. Chromium can 
alter insulin sensitivity at the cellular level. The oligo-
peptide Apo-Low-Molecular-Weight-Chromium bind-
ing peptide (also known as Apo-chromoduline) plays 
an important role in potentiating the insulin response 
in insulin sensitive cells[18,19]. The Apo-chromoduline is 
loaded intracellularly with a maximum of  four chromium 
ions. Chromium-loaded Apo-chromoduline is called 
Holo-chromoduline. The Holo-chromoduline molecule 
binds to the insulin receptor and potentiates the insulin 
response by activating the receptor. The degree of  insulin 
receptor activation depends on the number of  chromium 
ions bound to this peptide, with a minimum of  0 and a 
maximum of  4 ions. This chromium binding may lead to 
an 8-fold difference in insulin receptor activation (when 
4 ions are bound compared to 0). Experiments using rat 
adipocyte cells with equal serum insulin concentrations 
confirmed that insulin receptor activation is eight times 
stronger in the presence of  chromium than in the ab-
sence of  chromium[18].
ADVERSE EFFECTS OF CHROMIUM
Several cell culture and animal studies using supraphysi-
ological chromium doses yielded results suggesting that 
chromium may increase DNA damage[20-23]. Chromium 
is not unique in this respect; a number of  other nutrients 
such as vitamins A and D, nicotinic acid, and selenium 
have also been implicated in causing toxicity when taken 
in excess[24]. Clinical trials of  oral chromium supplementa-
tion did not demonstrate toxicity in patients on parenteral 
nutrition[24,25]. We could not find long-term chromium 
safety studies. The DNA damage identified in cases of  
supraphysiological trivalent chromium concentrations did 
not translate into potentially carcinogenic effects when a 
more physiological dose of  oral trivalent chromium was 
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used in humans[24,26].
CLINICAL EVIDENCE FOR CHROMIUM 
USE 
In 1997, the intervention trial by Anderson et al[27] was 
one of  the first chromium-intervention studies in pa-
tients with type 2 diabetes. In this randomized controlled 
trial, chromium picolinate supplements or placebo were 
administered to 180 Chinese patients with type 2 diabetes. 
The patients were randomized into three groups: placebo, 
200 mg chromium, and 1000 mg of  chromium daily. After 
four months, the hemoglobin A1c (HbA1c) levels in the 
placebo group were unchanged (8.5%), while they decreased 
significantly in the 200 mg group, from 8.5% to 7.5%, and 
decreased in the 1000 mg group, from 8.5% to 6.6%. 
In 2007, Balk et al[28] performed a systematic review 
of  randomized controlled trials investigating chromium 
supplementation in patients with type 2 diabetes. At that 
time, 14 studies with 18 different chromium-based inter-
ventions had been performed using HbA1c levels as an 
endpoint. In 11 out of  these 14 trials, there was no sig-
nificant effect of  chromium supplementation. The review 
by Balk et al[28] concluded that, due to the poor quality 
and heterogeneity of  the data, additional studies addressing 
these limitations were needed before definitive claims could 
be made about the effect of  chromium supplementation[28]. 
Nevertheless, the meta-analysis by Balk et al[28] reported an 
overall significant effect of  chromium supplementation 
on HbA1c levels (-0.6%; 95%CI: -0.9% to -0.2%). This 
-0.6% mean benefit was largely due to the inclusion of  
the data reported by Anderson et al[27]. When the An-
derson study was excluded, the effect of  chromium on 
HbA1c levels was -0.3% (95%CI: -0.5% to -0.1%; NS)[28]. 
It should be noted however, that the Anderson study was 
inadequately blinded with concerns for detection bias and 
selection bias, and should be considered to be of  poor-
methodological quality[27,28]. 
Significant effects in the meta-analysis were only 
found in studies with poor methodological quality or in 
studies sponsored by chromium supplement producing 
companies. In addition, the effects of  chromium supple-
mentation were shown to be absent or non-relevant after 
stratifying the studies according to methodological qual-
ity, sponsor involvement, and a western vs non-western 
study location[6,29].
After the review written by Balk et al[28], a second 
Dutch double blind trial was performed in 2008 that 
studied the effects of  chromium on HbA1c levels in 
patients with type 2 diabetes[29]. After 6 mo, the effect 
of  chromium supplementation compared to placebo 
on HbA1c levels was 0.24% (95%CI: -0.06% to 0.54%). 
HbA1c levels were lower in the placebo group compared 
with the chromium group. All of  the trials that have been 
performed had a relatively short follow-up period. No 
studies have been performed with sufficient follow-up 
and the ability to reliably investigate cardiovascular and/
or microvascular end-points. All studies used surrogate 
end-points. None of  the trials investigated whether pa-
tients had risk factors for chromium deficiency.
Although this review focuses on the most relevant 
method of  estimating glycemic control (HbA1c lev-
els)[30-32], several studies investigated the effect of  chromi-
um on other markers of  glycemic control[11,13,33-35]. Meta-
analyses showed that chromium supplementation did 
not improve fasting plasma glucose levels[33,36] and had 
no clinically relevant effect on body weight in individuals 
with or without diabetes[37-39].
DISCUSSION
Chromium plays a role in insulin physiology, and severe 
chromium deficiency can lead to insulin resistance. Chro-
mium supplementation may be beneficial in rare cases 
of  prolonged total parental nutrition when standard 
chromium supplementation is lacking[6]. Despite the lack 
of  sufficient evidence that chromium supplementation 
improves glycemic control[28,29], chromium is still widely 
marketed as an effective supplement for improving glyce-
mic control in patients with type 2 diabetes.
Do we need to worry that a low chromium status 
contributes to hyperglycemia in our patients? 
For the average patient with type 2 diabetes, the answer 
is no. Trivalent chromium is sufficiently available in food, 
and the occurrence of  severe chromium deficiency is 
highly unlikely. The sparse evidence that chromium sup-
plementation might have effects on glycemic control in a 
broader population is derived from studies with impor-
tant methodological flaws[27,28]. Well-performed trials and 
meta-analyses consistently show that there is no evidence 
for consistent beneficial effects on glycemic control (as 
assessed by HbA1c levels) that support prescribing chro-
mium supplements to patients with type 2 diabetes[6,40]. 
Furthermore, the long-term safety of  chromium supple-
mentation has not been established. 
Is all hope lost for chromium supplementation in 
patients with type 2 diabetes? 
An important concern when interpreting the data from 
studies investigating chromium effects is the lack of  a 
validated and precise estimate of  chromium status. There 
is no reliable method for assessing the body’s chromium 
status, and there is no information on the bioavailabil-
ity of  the different forms of  chromium[41]. Performing 
randomized trials in patients with type 2 diabetes will 
become interesting only when we can properly assess 
the chromium status in patients at risk for chromium 
deficiency and when clinically relevant end points are de-
fined. 
Recommendations
Future research on chromium should focus on establish-
ing a reliable method for assessing the body’s chromium 
status. The bioavailability of  different forms of  chro-
mium in Western and non-Western patients should be 
investigated in order to define a potential effective dose 
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